Combine the power of CRISPR interference and CRISPR activation gene modulation by screening in parallel to remove the ambiguity in target identification
Horizon's dual screen CRISPRi/a service leverages the expertise used to generate these whole-genome CRISPR screens and combines them into one service that allows for the ability to identify drug-gene interactions through paired gene perturbation analysis.
CRISPRi/a screening service
CRISPRi/a screening is designed to avoid the issue of false positive hit identification sometimes seen when performing gene editing to amplify loci. The dual screen uses CRISPRi and CRISPRa in parallel to identify genes which result in sensitization by analyzing the effect of the opposing function. This approach offers a novel, powerful and systematic way to explore drug mechanisms of action, identify novel bio-markers and provide targets for the development of combination therapies.
- Explore drug mechanisms of action
- Identify novel biomarkers
- Identify new combination therapy targets
- De-orphan and reposition drugs for new therapeutic applications
Horizon’s CRISPRi/a platform
Our dual CRISPRi/a screening platform has been developed and optimized to ensure it’s the gold-standard in drug-gene interaction screening. The platform allows for deep insights into the biological effects of down- and up-regulating genes in parallel within the same experimental model. The service offers:
- Both pooled lentiviral and arrayed synthetic reagent options
- Cell line(s) from a pre-optimized cell line list or cell line evaluation prior to the screen
- Human whole-genome CRISPRi and CRISPRa library or custom designed sub-library
- Customizable screen design
- Next-generation sequencing and bioinformatics analysis with hit nominations
- Project timeline of 12-24 weeks
CRISPRi/a platform deliverables:
- A list of genes of which inhibition/activation alters response to the compound of interest
- A final report containing experimental design, all raw & analyzed data and conclusions of the study
CRISPRi/a case study data
Identification of pathway modulators affecting both drug sensitivity and resistance as shown with the triggers to apoptosis on vemurafenib through the controlling components MCL1, BIM and NOXA.